Table 1.
Baseline demographic and clinical characteristics
| Parameter | Sitagliptin (n = 58) | α-Glucosidase inhibitor (n = 58) | P-value* |
|---|---|---|---|
| Age (years) | 57.6 ± 12.9 | 59.3 ± 11.3 | 0.45 |
| Sex | |||
| Male | 38 (65.5) | 36 (62.1) | 0.70 |
| Female | 20 (34.5) | 22 (37.9) | 0.70 |
| Height (m) | 1.64 ± 0.10 | 1.62 ± 0.091 | 0.26 |
| Weight (kg) | 70.2 ± 14.2 | 69.8 ± 16.3 | 0.87 |
| BMI (kg/m2) | 25.9 ± 4.3 | 26.3 ± 4.6 | 0.66 |
| Systolic blood pressure (mmHg) | 132.0 ± 13.7 | 132.9 ± 14.9 | 0.73 |
| Diastolic blood pressure (mmHg) | 79.9 ± 10.6 | 79.5 ± 11.0 | 0.81 |
| Duration of diabetes (years) | 6.7 ± 6.4 | 6.8 ± 5.5 | 0.97 |
| HbA1c (%) | 7.6 ± 0.70 | 7.6 ± 0.74 | 0.60 |
| Fasting plasma glucose (mmol/L) | 7.7 ± 1.7 | 7.4 ± 1.7 | 0.33 |
| Fasting C-peptide (mmol/L) | 0.61 ± 0.36 | 0.67 ± 0.34 | 0.40 |
| Fasting insulin (pmol/L) | 51.6 ± 44.2 | 61.5 ± 50.7 | 0.27 |
| HOMA-β | 36.2 ± 26.6 | 52.6 ± 54.9 | 0.045 |
| HOMA-IR | 2.7 ± 3.7 | 2.8 ± 2.4 | 0.88 |
| Fasting lipid profiles | |||
| Total cholesterol (mmol/L) | 5.0 ± 0.88 | 4.9 ± 0.88 | 0.49 |
| LDL cholesterol (mmol/L) | 2.8 ± 0.68 | 2.8 ± 0.71 | 0.69 |
| HDL cholesterol (mmol/L) | 1.4 ± 0.41 | 1.4 ± 0.34 | 0.94 |
| Triglycerides (mmol/L) | 1.7 ± 1.2 | 1.6 ± 1.0 | 0.59 |
| Non-HDL cholesterol (mmol/L) | 3.7 ± 0.85 | 3.5 ± 0.86 | 0.40 |
| Prior antidiabetic treatment | |||
| Metformin | 47 (81.0) | 46 (79.3) | 0.82 |
| Pioglitazone | 11 (19.0) | 12 (20.7) | 0.82 |
| Concomitant treatments | |||
| Antihypertensive drugs | 29 (50.0) | 27 (46.6) | 0.71 |
| Antihyperlipemic drugs | 28 (48.3) | 26 (44.8) | 0.71 |
Data are presented as mean ± standard deviation values, or n (%). *P-values for differences between the sitagliptin and α-glucosidase inhibitor groups. BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-β, homoeostasis model assessment of β-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance.